Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-494-8144


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit or follow ARIAD on Twitter (@ARIADPharm).

 Key Statistics

Ownership: Public

Web Site: Ariad Pharmaceuticals, Inc.
Symbol: ARIA

 Company News
Ariad Pharmaceuticals, Inc. (ARIA) To Webcast Conference Call On Third Quarter 2014 Financial Results 10/15/2014 9:10:34 AM
Ariad Pharmaceuticals, Inc. (ARIA)’s Harvey Berger Says He’s "Absolutely" Secure In His Role As CEO 10/13/2014 6:12:39 AM
PRAC Decision On Leukemia Drug Good News For Ariad Pharmaceuticals, Inc. (ARIA), Says Analyst 10/10/2014 3:24:40 PM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Recommendation For Iclusig By The Pharmacovigilance Risk Assessment Committee Of The European Medicines Agency 10/10/2014 8:04:25 AM
Ariad Pharmaceuticals, Inc. (ARIA), Bellicum Pharmaceuticals, Inc. Revise Pact; Ariad Will Receive $50 Million In Three Installments 10/6/2014 6:02:39 AM
Ariad Pharmaceuticals, Inc. (ARIA)'s Lung Cancer Drug Wins Breakthrough Therapy Status 10/2/2014 6:19:18 AM
Ariad Pharmaceuticals, Inc. (ARIA) Presents Updated Clinical Data On AP26113 In Patients With ALK+ Non-Small Cell Lung Cancer 9/29/2014 11:33:18 AM
Departure Of Ariad Pharmaceuticals, Inc. (ARIA) Director Sparks Speculation That CEO Berger's Days Are Numbered 9/23/2014 7:18:32 AM
Leukemia Drug Troubles Force Ariad Pharmaceuticals, Inc. (ARIA) To Shrink Size Of Footprint In Kendall Square 8/28/2014 7:00:28 AM
Ariad Pharmaceuticals, Inc. (ARIA) Reports Second Quarter 2014 Financial Results And Development Progress 8/6/2014 9:32:35 AM